Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06269484 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT06269484 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 73 participants.
The verdict
NCT06269484, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin and zibotentan monotherapy as compared to placebo in patients with cirrhosis.
Interventions
- DRUG Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)
- DRUG Zibotentan + placebo (placebo matching dapagliflozin tablet)
- DRUG Zibotentan + dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2024-02-15 |
| Est. Completion | 2024-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06269484
The ClinicalTrials.gov registry entry for NCT06269484 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) is the first listed.
NCT06269484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06269484 about?
NCT06269484 is a clinical study titled "A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK". This is a Phase IIb multicentre, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the safety of zibotentan/dapagliflozin in combination as compared to zibotentan monotherapy as well as zibotentan/dapagliflozin and zibotentan monotherapy as compared to placebo in patient...
What is the current status of trial NCT06269484?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2024-02-15. Estimated completion is 2024-12-11.
What interventions are being tested in trial NCT06269484?
The interventions under investigation include: Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) (DRUG), Zibotentan + placebo (placebo matching dapagliflozin tablet) (DRUG), Zibotentan + dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT06269484?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.